Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

פריטים דומים

• Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis
  מאת: Fala, Loretta
  יצא לאור: (2015)
• Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
  מאת: Fala, Loretta
  יצא לאור: (2016)
• Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
  מאת: Fala, Loretta
  יצא לאור: (2015)
• Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
  מאת: Fala, Loretta
  יצא לאור: (2015)
• Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
  מאת: Malakouti, Mona, et al.
  יצא לאור: (2016)